Premium
A Pasteurized Antithrombin III Concentrate for Clinical Use
Author(s) -
SmithM J.K.,
Winkelman L.,
Evans D.R.,
Haddon M.E.,
Sims G.
Publication year - 1985
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1985.tb00192.x
Subject(s) - cryoprecipitate , prothrombin complex , chromatography , sephadex , pasteurization , chemistry , elution , antithrombin , prothrombin complex concentrate , yield (engineering) , size exclusion chromatography , heparin , food science , fibrinogen , biochemistry , medicine , coagulation , materials science , warfarin , metallurgy , enzyme , atrial fibrillation
. A method for large‐scale production of a pasteurized antithrombin III (AT III) concentrate for therapeutic use has been adapted from published methods. It includes the following steps: (1) batchwise adsorption onto heparin‐Sepharose from plasma depleted of cryoprecipitate and prothrombin complex; (2) chromatographic elution at high salt concentration; (3) pasteurization for 10 h at 60°C in the presence of added citrate ion; (4) desalting on Sephadex G‐25, and (5) sterile filtration and freeze‐drying. Seven batches prepared in this manner gave a mean yield of 269 UAT III/kg plasma. The product passed all the usual animal safety and pyrogenicity tests and has been used successfully in several courses of treatment of congenital deficiencies.